A new ONTARGET imaging study has shown no difference between ramipril, telmisartan, or the combination in the reduction of left ventricular mass. The MRI study, say investigators, closely parallels the main findings from ONTARGET, showing no clear advantage to combination therapy. Heartwire
The Endocrine Society clinical practice guideline reviews case detection, diagnosis, and treatment of patients with primary aldosteronism. Medscape Medical News
Transdermal delivery of estrogen does not appear to be linked with the same risk for venous thromboembolism as that seen with oral estrogen, a meta-analysis suggests. Medscape Medical News
